Results 171 to 180 of about 71,769 (253)

BCOR-CCNB3 fusion-positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up. [PDF]

Front Oncol
Oike N, Imai R, Ogose A, Ariizumi T, Murayama Y, Miyazaki T, Kimura K, Umezu H, Kawashima H.   +8 more
europepmc   +1 more source

Chemical Profiles, Pharmacological Insights, and In Silico Studies of Antidesma montanum Blume: An Experimental and Computer‐Aided Approach

eFood, Volume 7, Issue 4, August 2026.
Antidesma montanum, an edible wild plant, shows notable nutraceutical and pharmacological potential. Methanol extract profiling (GC–MS) identified bioactive metabolites. In vitro, in vivo, and in silico studies demonstrated significant antidiabetic, anthelmintic, anxiolytic, antidepressant, and antidiarrheal activities, supported by strong molecular ...
Naureen Banu, Najmul Alam, Sadia Farid Jhuma, Mohammad Nazmul Islam, Shady A. Alghazali, Md Abdul Awal, Sanjida Islam, Hafsa Siddiqua, Shafinaz Nur, Md. Sohel Rana   +9 more
wiley   +1 more source

Single-center analysis of relapse risk factors and prognosis in 256 cases of ETV6::RUNX1-positive pediatric acute lymphoblastic leukemia. [PDF]

BMC Pediatr
Hu B, Hu F, He H, Kong L.
europepmc   +1 more source

First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo, Lorenzo Falchi, Per‐Ola Andersson, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Jacob H. Christensen, Michael R. Clausen, Alexander Fosså, Pilar G. Prieto, Eliza A. Hawkes, Judit M. Jørgensen, Yasmin H. Karimi, Catharina Lewerin, Joost S. P. Vermaat, Björn E. Wahlin, Poliana Patah, Christopher Morehouse, Malene Risum, Zhu Li, Jennifer Marek, Joshua D. Brody   +21 more
wiley   +1 more source

Combinatorial chemistry identifies additional compounds that selectively inhibit DLK-dependent retrograde signaling while minimally affecting other axonal roles of DLK. [PDF]

Sci Rep
Zhang X, Jeong H, Melenski E, Gordon J, Childers WE, Thomas GM.   +5 more
europepmc   +1 more source

Expression and prognostic impact of CD73 in classical Hodgkin lymphoma. [PDF]

Ann Hematol
Liu B, He C, Liu H, Ma G, Zhang S, Liu Y, Liu C, Li K, Wang Y, Liu Y, Yue M, Liu C, Wang X, Yin S, Li Z.   +14 more
europepmc   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

International Journal of Cancer, Volume 159, Issue 3, Page 719-728, 1 August 2026.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park, Danbee Kang, Jin Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Hojoon Lee, Hyuna Lim, Xerxes Pundole, Juhee Cho, Myung‐Ju Ahn   +11 more
wiley   +1 more source

First Successful Treatment Reported with Pembrolizumab in a Patient Diagnosed with Choriocarcinoma in Hungary. [PDF]

Life (Basel)
Lakatos KF, Kalmár L, Lahm E, Bíró EG, Fülöp V.   +4 more
europepmc   +1 more source

Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell‐Activating Properties in B Cell Lymphoma

Journal of Extracellular Vesicles, Volume 15, Issue 8, August 2026.
B cell lymphoma‐derived EVs are intrinsically neutral or suppressive with respect to NK cell activity (panel 1). In the context of rituximab treatment, NK cytotoxicity is enhanced by antibody‐dependent cell‐mediated cytotoxicity (panel 2). Herein we show that, in addition, rituximab recognition of EV‐associated CD20 generates immune complexes that ...
Adrián V. Otero, Paula Soledad Pérez, Belen Gaete‐Ramírez, Gregorio Cordini, Matías Norte, Enriqueta Martínez, Nicolás Marsol, Cecilia Malusardi, Sofía Rivarola, Ana Cantillo, María Luz Leicaj, Constanza Russo, Juan Quarroz Braghini, Federico Penas, Glenda Ernst, Cecilia Cabral, Silvina Palmer, Manuel Varas‐Godoy, Lourdes Arruvito, Matías Ostrowski   +19 more
wiley   +1 more source

Pharmacogenomics of treatment toxicities in pediatric B-Cell ALL: toward safer precision therapy. [PDF]

Front Pharmacol
Lameri M, Kamergi T, Brahim A, Abdallah I, Mezzi N, Zerei S, Benkahla A, Chaabane M, Drira C, Felfel H, Ben Abdennebi Y, Khrouf MR, Amor D, Romdhane L, Chaker H.   +14 more
europepmc   +1 more source